On the occasion of the 35^th anniversary of Pudong's development and opening-up, the "Win-Win Pudong, Create the Future" Leading Zone 2025 Conference on Investment Promotion, Business Environment Enhancement, and Development Acceleration was held in Pudong New Area on February 6, 2025. This event sounded the "charge" for the Leading Zone's endeavors in the new year and injected fresh momentum into Pudong's mission to become a global innovation hub for biopharmaceuticals. At this conference, UnionClin successfully signed as one of the seven key industrial projects in Zhangjiang High-tech Park in Pudong, further driving the high-quality development of Pudong's biopharmaceutical industry. 

Attending the event were Li Zheng, Member of the Standing Committee of the Municipal Party Committee and Secretary of the Pudong New Area District Committee, and Wu Jincheng, Deputy Secretary-General of the Municipal Government, Deputy Secretary of the Pudong New Area District Committee, and District Mayor. Together, they launched the "Win-Win Pudong, Create the Future"—2025 "Pudong Investment Promotion Year."

As a key industrial project, this signing not only marks a significant milestone in UnionClin's new journey but also reflects the New Area government's strong emphasis and robust support for the biopharmaceutical industry. Leveraging Zhangjiang's innovative ecosystem and policy advantages, UnionClin will further enhance its service capabilities, improve the efficiency and quality of clinical research services, leverage geographical advantages to better serve innovative drug development enterprises, contribute to the innovative development of Pudong's biopharmaceutical industry, and remain committed to becoming a clinical CRO with the most professional capabilities in oncology, autoimmune diseases, infections, neurology, and cardiovascular fields. 

Pudong New Area stands as a major hub for China's biopharmaceutical industry, with Zhangjiang Park being acclaimed as the "Zhangjiang Pharma Valley," boasting a comprehensive industrial ecosystem and abundant scientific research resources. In recent years, Pudong New Area has implemented a series of policy measures to support high-quality development in the biopharmaceutical industry, providing an optimal growth environment for numerous enterprises. 

The 33 projects signed this time focus on five key sectors: priority industries, urban renewal, infrastructure, financing services for small and micro enterprises, and data elements valorization, with total investments exceeding 130 billion yuan, demonstrating Pudong's ambition to build a global resource allocation hub. UnionClin will seize policy opportunities and leverage its professional, internationalized clinical research services for innovative drugs to accelerate market approvals, collaborating with Zhangjiang to write a new chapter in building a world-class biopharmaceutical industry cluster.